CN103298801A - 作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物 - Google Patents

作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物 Download PDF

Info

Publication number
CN103298801A
CN103298801A CN2011800550665A CN201180055066A CN103298801A CN 103298801 A CN103298801 A CN 103298801A CN 2011800550665 A CN2011800550665 A CN 2011800550665A CN 201180055066 A CN201180055066 A CN 201180055066A CN 103298801 A CN103298801 A CN 103298801A
Authority
CN
China
Prior art keywords
methyl
pyrazol
piperidines
carboxylic acid
cyano group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800550665A
Other languages
English (en)
Chinese (zh)
Inventor
V·马希蒂
K·F·麦克卢尔
M·J·芒奇霍夫
小R·P·鲁宾逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Pfizer Inc
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103298801(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN103298801A publication Critical patent/CN103298801A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800550665A 2010-11-23 2011-11-09 作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物 Pending CN103298801A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23
US61/416,441 2010-11-23
PCT/IB2011/054996 WO2012069948A1 (en) 2010-11-23 2011-11-09 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Publications (1)

Publication Number Publication Date
CN103298801A true CN103298801A (zh) 2013-09-11

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800550665A Pending CN103298801A (zh) 2010-11-23 2011-11-09 作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物

Country Status (26)

Country Link
EP (1) EP2643310A1 (ja)
JP (1) JP2013543885A (ja)
KR (1) KR20130083915A (ja)
CN (1) CN103298801A (ja)
AP (1) AP2013006809A0 (ja)
AR (1) AR088121A1 (ja)
AU (1) AU2011333427A1 (ja)
BR (1) BR112013011865A2 (ja)
CA (1) CA2814231A1 (ja)
CL (1) CL2013001054A1 (ja)
CO (1) CO6801716A2 (ja)
CR (1) CR20130139A (ja)
CU (1) CU20130059A7 (ja)
DO (1) DOP2013000102A (ja)
EA (1) EA201370118A1 (ja)
EC (1) ECSP13012630A (ja)
GT (1) GT201300135A (ja)
MA (1) MA34805B1 (ja)
MX (1) MX2013004083A (ja)
NI (1) NI201300044A (ja)
PE (1) PE20140409A1 (ja)
SG (1) SG189830A1 (ja)
TW (1) TWI433843B (ja)
UY (1) UY33742A (ja)
WO (1) WO2012069948A1 (ja)
ZA (1) ZA201302362B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN106631992A (zh) * 2017-01-05 2017-05-10 桑迪亚医药技术（上海）有限责任公司 一种4‑氧‑3,4‑二氢‑2h‑吡啶‑1‑甲酸叔丁酯的合成方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017140771A1 (en) 2016-02-18 2017-08-24 Syngenta Participations Ag Pesticidally active pyrazole derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123992A1 (en) * 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
CN101754962A (zh) * 2007-07-19 2010-06-23 麦它波莱克斯股份有限公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
CN102459222A (zh) * 2009-06-05 2012-05-16 辉瑞大药厂 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754962A (zh) * 2007-07-19 2010-06-23 麦它波莱克斯股份有限公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
WO2009123992A1 (en) * 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
CN102459222A (zh) * 2009-06-05 2012-05-16 辉瑞大药厂 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN106631992A (zh) * 2017-01-05 2017-05-10 桑迪亚医药技术（上海）有限责任公司 一种4‑氧‑3,4‑二氢‑2h‑吡啶‑1‑甲酸叔丁酯的合成方法

Also Published As

Publication number Publication date
KR20130083915A (ko) 2013-07-23
GT201300135A (es) 2015-02-19
NI201300044A (es) 2013-08-01
CA2814231A1 (en) 2012-05-31
MA34805B1 (fr) 2014-01-02
AU2011333427A1 (en) 2013-04-11
JP2013543885A (ja) 2013-12-09
DOP2013000102A (es) 2013-07-15
BR112013011865A2 (pt) 2016-08-23
CU20130059A7 (es) 2013-06-28
AR088121A1 (es) 2014-05-14
UY33742A (es) 2012-06-29
WO2012069948A1 (en) 2012-05-31
EP2643310A1 (en) 2013-10-02
CO6801716A2 (es) 2013-11-29
AP2013006809A0 (en) 2013-04-30
SG189830A1 (en) 2013-06-28
TWI433843B (zh) 2014-04-11
TW201300373A (zh) 2013-01-01
CR20130139A (es) 2013-06-28
MX2013004083A (es) 2013-06-13
CL2013001054A1 (es) 2013-09-27
EA201370118A1 (ru) 2013-12-30
PE20140409A1 (es) 2014-03-23
ZA201302362B (en) 2014-06-25
ECSP13012630A (es) 2013-07-31

Similar Documents

Publication Publication Date Title
CN102459222B (zh) 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物
CN103298801A (zh) 作为gpr 119 调节剂的4-（5-氰基-吡唑-1-基）哌啶衍生物
CN111372925B (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN111647000B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
EP4349840A2 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
CN109153648A (zh) 具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物
CN101115740A (zh) 作为代谢调节剂的经取代吡啶基和嘧啶基衍生物和相关疾病的治疗
TW201704232A (zh) 雙環酮磺醯胺化合物
CN101970420A (zh) 噁二唑衍生物
EA032304B1 (ru) Спироциклические соединения в качестве ингибиторов триптофангидроксилазы
CN103189377A (zh) N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
CN115989235A (zh) 使用氨基酸化合物治疗呼吸系统疾病的方法
US10717727B2 (en) Pyridinium compounds
CN102432598A (zh) 三环化合物、其制备方法及其在医药上的应用
JP2019099571A (ja) Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CN108473461A (zh) 喹唑啉酮衍生物、其制备方法、药物组合物及应用
EP2504342A1 (en) Imidazo-pyrazoles as gpr119 inhibitors
CN103261165A (zh) 胰高血糖素受体调节剂
JP6378752B2 (ja) ピロリジン誘導体、その医薬組成物及び使用
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
WO2005090340A1 (ja) ピペリジン－１－カルボキサミド誘導体
CN109206360B (zh) 咔唑酰胺类衍生物或其盐及其制备方法和用途
WO2011088031A1 (en) Compounds and methods
RU2777979C2 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2
TW202416988A (zh) 含氮雜環的多環化合物的游離鹼晶型及其製備方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188788

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130911

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1188788

Country of ref document: HK